MX357167B - Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer. - Google Patents

Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.

Info

Publication number
MX357167B
MX357167B MX2013004790A MX2013004790A MX357167B MX 357167 B MX357167 B MX 357167B MX 2013004790 A MX2013004790 A MX 2013004790A MX 2013004790 A MX2013004790 A MX 2013004790A MX 357167 B MX357167 B MX 357167B
Authority
MX
Mexico
Prior art keywords
cadherin
subdomains
methods
polypeptides
cells
Prior art date
Application number
MX2013004790A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004790A (es
Inventor
Brouxhon Sabine
Kerry O'banion M
Kyrkanides Stephanos
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of MX2013004790A publication Critical patent/MX2013004790A/es
Publication of MX357167B publication Critical patent/MX357167B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
MX2013004790A 2010-10-27 2011-10-27 Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer. MX357167B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40736710P 2010-10-27 2010-10-27
PCT/US2011/058076 WO2012058418A2 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Publications (2)

Publication Number Publication Date
MX2013004790A MX2013004790A (es) 2014-01-17
MX357167B true MX357167B (es) 2018-06-28

Family

ID=45994754

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004790A MX357167B (es) 2010-10-27 2011-10-27 Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.
MX2018007983A MX2018007983A (es) 2010-10-27 2013-04-26 Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007983A MX2018007983A (es) 2010-10-27 2013-04-26 Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.

Country Status (13)

Country Link
US (4) US20130287784A1 (enExample)
EP (1) EP2632489B1 (enExample)
JP (1) JP6243737B2 (enExample)
KR (1) KR20140075639A (enExample)
CN (1) CN103582494A (enExample)
AU (1) AU2011319777B2 (enExample)
BR (1) BR112013010535A2 (enExample)
CA (1) CA2816358A1 (enExample)
ES (1) ES2784385T3 (enExample)
MX (2) MX357167B (enExample)
RU (1) RU2013123792A (enExample)
SG (3) SG189547A1 (enExample)
WO (1) WO2012058418A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
CN104519899A (zh) * 2012-03-15 2015-04-15 纽约州立大学研究基金会 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法
US9411750B2 (en) 2012-07-30 2016-08-09 International Business Machines Corporation Efficient calibration of a low power parallel data communications channel
US9474034B1 (en) 2015-11-30 2016-10-18 International Business Machines Corporation Power reduction in a parallel data communications interface using clock resynchronization
WO2017156463A1 (en) 2016-03-10 2017-09-14 Cable Television Laboratories, Inc. Systems and methods for latency reduction
US10492104B2 (en) 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
US10321351B2 (en) 2017-03-02 2019-06-11 Cable Television Laboratories, Inc. System and method for grant assignment
BR112018075654B1 (pt) 2016-06-10 2022-04-05 Veritas Biotecnologia Ltda Anticorpos monoclonais, composições farmacêuticas, linhagem celular de hibridoma, usos dos referidos anticorpos monoclonais e métodos para detectar a expressão de cdh1
US10420085B2 (en) 2016-10-07 2019-09-17 Cable Television Laboratories, Inc. System and method for grant assignment
US12225536B2 (en) 2016-10-07 2025-02-11 Cable Television Laboratories, Inc. System and method for grant assignment
EP3791570A4 (en) 2018-05-11 2022-01-26 Axon Enterprise, Inc. SYSTEMS AND METHODS OF CROSS-EDITING
WO2021141492A1 (en) * 2020-01-10 2021-07-15 Kling Biotherapeutics B.V. Epithelial cadherin-specific antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR940009084B1 (ko) 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AU5669494A (en) * 1992-11-17 1994-06-08 Yale University Human homolog of the e-cadherin gene and methods based thereon
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6723320B2 (en) * 1996-07-24 2004-04-20 Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
WO2002081655A2 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2004064765A2 (en) 2003-01-23 2004-08-05 University Of Rochester Herpesvirus amplicon particles
CA2760642A1 (en) * 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody

Also Published As

Publication number Publication date
JP2014500862A (ja) 2014-01-16
ES2784385T3 (es) 2020-09-24
SG189547A1 (en) 2013-05-31
MX2013004790A (es) 2014-01-17
US20210380671A1 (en) 2021-12-09
CA2816358A1 (en) 2012-05-03
EP2632489A4 (en) 2014-06-18
WO2012058418A3 (en) 2012-07-19
BR112013010535A2 (pt) 2017-11-07
SG10201604467PA (en) 2016-07-28
RU2013123792A (ru) 2014-12-10
AU2011319777B2 (en) 2016-12-08
US20160046701A1 (en) 2016-02-18
US20190352380A1 (en) 2019-11-21
MX2018007983A (es) 2023-02-23
CN103582494A (zh) 2014-02-12
US20130287784A1 (en) 2013-10-31
EP2632489B1 (en) 2020-01-15
AU2011319777A1 (en) 2013-05-23
SG10202100921YA (en) 2021-03-30
KR20140075639A (ko) 2014-06-19
EP2632489A2 (en) 2013-09-04
JP6243737B2 (ja) 2017-12-06
WO2012058418A2 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
MX2018007983A (es) Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.
Qiu et al. Breaking physical barrier of fibrotic breast cancer for photodynamic immunotherapy by remodeling tumor extracellular matrix and reprogramming cancer-associated fibroblasts
Yan et al. Metal-phenolic nanomedicines regulate T-cell antitumor function for sono-metabolic cancer therapy
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
Dutra-Oliveira et al. Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2582727A4 (en) ANTIBODIES TO ENDOPLASMINE AND ITS USE
BR112012013664A2 (pt) rabdovírus oncolítico
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2012061443A3 (en) Compositions of a peptide targeting system for treating cancer
IN2014DN09221A (enExample)
IN2015KN00350A (enExample)
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
NZ715177A (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
Fernández-Tabanera et al. CD44 in sarcomas: a comprehensive review and future perspectives
WO2019067951A3 (en) Cd1d and tcr-nkt cells
EA201491259A1 (ru) Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
MX2024003779A (es) Agentes de union dirigidos a celulas tumorales que expresan trop2.
MX2020011290A (es) Ligandos dirigidos a la integrina y sus usos.
WO2021003050A3 (en) Cd38-binding agents and uses thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ALLNEX NETHERLANDS B.V.

FG Grant or registration